68 Ga-Labeled Fibroblast Activation Protein Inhibitor ( 68 Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68 Ga-FAPI PET Observational Trial
Journal of Nuclear Medicine · 2023-12 · 64 (12) · 1910-1917
DOI: 10.2967/jnumed.122.264827 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 16.11.2023. Verfasst von Lukas Kessler und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Hauptthemen laut MEDLINE: Adenocarcinoma, Pancreatic Neoplasms, Cancer-Associated Fibroblasts, Quinolines. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
The fibroblast activation protein (FAP) is highly expressed on carcinoma-associated fibroblasts in the stroma of pancreatic cancer and thus is a promising target for imaging and therapy. Preliminary data on PET imaging with radiolabeled FAP inhibitors (FAPIs) demonstrate superior tumor detection. Here we assess the accuracy of FAP-directed PET in patients with pancreatic cancer.
Methods
Of 64 patients with suspected or proven pancreatic cancer, 62 (97%) were included in the data analysis of the 68Ga-FAPI PET observational trial (NCT04571086). All of these patients underwent contrast-enhanced CT, and 38 patients additionally underwent 18F-FDG PET. The primary study endpoint was the association of 68Ga-FAPI PET uptake intensity and histopathologic FAP expression. Secondary endpoints were detection rate, diagnostic performance, interreader reproducibility, and change in management. Datasets were interpreted by 2 masked readers.
Results
The primary endpoint was met: The association between 68Ga-FAPI SUVmax and histopathologic FAP expression was significant (Spearman r, 0.48; P = 0.04). For histopathology-validated lesions, 68Ga-FAPI PET showed high sensitivity and positive predictive values (PPVs) on per-patient (sensitivity, 100%; PPV, 96.3%) and per-region (sensitivity, 100%; PPV, 97.0%) bases. In a head-to-head comparison versus 18F-FDG or contrast-enhanced CT, 68Ga-FAPI detected more tumor on a per-lesion (84.7% vs. 46.5% vs. 52.9%), per-patient (97.4% vs. 73.7% vs. 92.1%), or per-region (32.6% vs. 18.8% vs. 23.7%) basis, respectively. 68Ga-FAPI PET readers showed substantial overall agreement on the basis of the Fleiss κ: primary κ, 0.77 (range, 0.66-0.88). Minor and major changes in clinical management occurred in 5 patients (8.4%) after 68Ga-FAPI PET.
Conclusion
We confirmed an association of 68Ga-FAPI PET SUVmax and histopathologic FAP expression in pancreatic cancer patients. Additionally, we found high detection rate and diagnostic accuracy, superior to those of 18F-FDG PET/CT. 68Ga-FAPI might become a powerful diagnostic tool for pancreatic cancer work-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
- Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany.
- German Cancer Consortium (DKTK) (Partner Site University Hospital Essen) and German Cancer Research Center (DKFZ), Essen, Germany.
- Department of Medical Oncology, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.
- Department of General and Visceral Surgery, St. Josef Hospital Bochum, Ruhr-University Bochum, Bochum, Germany.
- Department of Hematology and Oncology with Palliative Care, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
Zitieren
APA
Kessler, L., Hirmas, N., Pabst, K. M., Hamacher, R., Ferdinandus, J., Schaarschmidt, B. M., Milosevic, A., Nader, M., Umutlu, L., Uhl, W., Reinacher-Schick, A., Lugnier, C., Witte, D., Niedergethmann, M., Herrmann, K., Fendler, W. P., & Siveke, J. T. (2023). 68 Ga-Labeled Fibroblast Activation Protein Inhibitor ( 68 Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68 Ga-FAPI PET Observational Trial. Journal of Nuclear Medicine, 64(12), 1910-1917. https://doi.org/10.2967/jnumed.122.264827
Vancouver
Kessler L, Hirmas N, Pabst KM, Hamacher R, Ferdinandus J, Schaarschmidt BM, et al. 68 Ga-Labeled Fibroblast Activation Protein Inhibitor ( 68 Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68 Ga-FAPI PET Observational Trial. Journal of Nuclear Medicine. 2023;64(12):1910-1917. doi:10.2967/jnumed.122.264827
BibTeX
@article{Kessler2023,
author = {Kessler, Lukas and Hirmas, Nader and Pabst, Kim M and Hamacher, Rainer and Ferdinandus, Justin and Schaarschmidt, Benedikt M and Milosevic, Aleksandar and Nader, Michael and Umutlu, Lale and Uhl, Waldemar and Reinacher-Schick, Anke and Lugnier, Celine and Witte, David and Niedergethmann, Marco and Herrmann, Ken and Fendler, Wolfgang P and Siveke, Jens T},
title = {68 Ga-Labeled Fibroblast Activation Protein Inhibitor ( 68 Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68 Ga-FAPI PET Observational Trial},
journal = {Journal of Nuclear Medicine},
year = {2023},
volume = {64},
number = {12},
pages = {1910--1917},
doi = {10.2967/jnumed.122.264827}
}
EUVIMED